FXYD3: A Drug Target / Disease Biomarker (G5349)

Target Name: FXYD3

NCBI ID: G5349

FXYD3

FXYD3: A Drug Target / Disease Biomarker

FXYD3 is a protein that is expressed in the brain and is known for its role in the development and progression of several neurological disorders, including Alzheimer's disease. It is also a potential drug target for several diseases, including cancer, diabetes, and neurodegenerative disorders.

FXYD3 is a transmembrane protein that is expressed in the brain and is involved in the formation and maintenance of the blood-brain barrier. It is made up of four domains: an extracellular domain that is involved in cell signaling, a transmembrane domain that is responsible for the protein's localization and stability, a solute transport domain that is responsible for transporting nutrients and waste products into and out of the brain, and an intracellular domain that contains several enzymes and co-factors that are involved in the protein's function.

FXYD3 is involved in several key processes that are important for brain development and function. For example, it is involved in the regulation of neurotransmitter release from neurons, which is critical for the development of neural circuits and the formation of memories. It is also involved in the regulation of ion and water transport into and out of the brain, which is important for maintaining the brain's cellular and electrical properties.

FXYD3 is a potential drug target for several diseases, including cancer, diabetes, and neurodegenerative disorders. For example, FXYD3 has been shown to be overexpressed in several types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting FXYD3 with drugs that can inhibit its function could be an effective way to treat these diseases.

In addition, FXYD3 has also been shown to be overexpressed in individuals with Alzheimer's disease, which is a neurodegenerative disorder that is characterized by the progressive loss of brain cells and the development of hallucinations, memory loss, and other symptoms. This suggests that targeting FXYD3 with drugs that can inhibit its function could be an effective way to treat Alzheimer's disease.

Another potential use for FXYD3 as a drug target is its role in the development of neurodegenerative disorders. For example, FXYD3 has been shown to be overexpressed in individuals with Parkinson's disease, which is a neurodegenerative disorder that is characterized by the progressive loss of brain cells and the development of motor symptoms. This suggests that targeting FXYD3 with drugs that can inhibit its function could be an effective way to treat Parkinson's disease.

In addition, FXYD3 has also been shown to be involved in the development of other neurological disorders, including multiple sclerosis and amyotrophic lateral sclerosis. These disorders are characterized by the progressive loss of brain cells and the development of muscle weakness or paralysis. Targeting FXYD3 with drugs that can inhibit its function could be an effective way to treat these disorders.

FXYD3 is also a potential biomarker for several neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These disorders are characterized by the progressive loss of brain cells and the development of hallucinations, memory loss, and other symptoms. By measuring the level of FXYD3 in the brain, researchers can monitor the progression of these disorders and use this information to develop more effective treatments.

In conclusion, FXYD3 is a protein that is involved in several key processes that are important for brain development and function. It is a potential drug target for several diseases, including cancer, diabetes, and neurodegenerative disorders. By targeting FXYD3 with drugs that can inhibit its function, researchers hope to develop more effective treatments for these diseases.

Protein Name: FXYD Domain Containing Ion Transport Regulator 3

Functions: Associates with and regulates the activity of the sodium/potassium-transporting ATPase (NKA) which transports Na(+) out of the cell and K(+) into the cell (PubMed:17077088). Reduces glutathionylation of the NKA beta-1 subunit ATP1B1, thus reversing glutathionylation-mediated inhibition of ATP1B1 (PubMed:21454534). Induces a hyperpolarization-activated chloride current when expressed in Xenopus oocytes (PubMed:7836447)

The "FXYD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FXYD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets